Skip to main content
. 2022 Dec 8;28(12):2573–2583. doi: 10.1038/s41591-022-02126-1

Fig. 1. Patient flow diagram.

Fig. 1

The FAS included all patients who had received any IMP. The PP population comprised all patients who had received >3 doses of atezolizumab/placebo and >2 doses of PLD and could be evaluated for tumor response.